Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6783MR)

This product GTTS-WQ6783MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6783MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3504MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ4618MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ1425MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ2981MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ1752MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ302MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ4275MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ8636MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW